120. Hereditary dystonia Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 26 / Drugs : 19 - (DrugBank : 3) / Drug target genes : 2 - Drug target pathways : 2
Drugs and their primary sponsors and trial info
CoA
Oregon Health and Science University
2019 - NCT04182763 United States;
Deferiprone
Chiesi Canada Corp
2016 - NCT02635841 -
ISTITUTO NEUROLOGICO CARLO BESTA
2008 - EUCTR2008-003059-56-IT Italy;
Deferiprone 80 mg/mL oral solution
ApoPharma Inc
2015 Phase 3 EUCTR2014-001427-79-GB Germany;Italy;United Kingdom;United States;
ApoPharma Inc.
2015 Phase 3 EUCTR2014-001427-79-DE Germany;Italy;United Kingdom;United States;
2013 Phase 3 EUCTR2012-000845-11-IT Germany;Italy;Poland;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000845-11-DE Germany;Italy;Poland;United Kingdom;United States;
Deferiprone 80 mg/mL oral solution (Ferriprox)
ApoPharma Inc
2013 Phase 3 EUCTR2012-000845-11-GB Germany;Italy;Poland;United Kingdom;United States;
Deferiprone oral solution
ApoPharma
2014 Phase 3 NCT02174848 Germany;Italy;United Kingdom;United States;
2012 Phase 3 NCT01741532 Germany;Italy;Poland;United Kingdom;United States;
Deferiprone treated
First Affiliated Hospital of Fujian Medical University
2019 Early Phase 1 NCT04184453 China;
Desipramine
Duke University
2019 Phase 4 NCT03726996 United States;
FERRIPROX*100CPR RIV
ISTITUTO NEUROLOGICO CARLO BESTA
2008 - EUCTR2008-003059-56-IT Italy;
FOSMETPANTOTENATE DRUG SUBSTANCE
Retrophin, Inc.
2018 Phase 3 EUCTR2016-001955-29-FR Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-GB Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Serbia;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-CZ Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-PL Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-NO Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-DE Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Ferriprox
ApoPharma Inc
2015 Phase 3 EUCTR2014-001427-79-GB Germany;Italy;United Kingdom;United States;
Fosmetpantotenate
Retrophin, Inc.
2017 Phase 3 EUCTR2016-001955-29-ES Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Fosmetpantotenate (RE-024)
Travere Therapeutics, Inc.
2017 Phase 3 NCT03041116 Canada;Czechia;France;Germany;Italy;Norway;Poland;Spain;United States;
Fosmetpantotenato
RETROPHIN, INC
2017 Phase 3 EUCTR2016-001955-29-IT Canada;Czech Republic;Czechia;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Hematopoetic Stem Cell Transplantation
University of Pittsburgh
2012 - NCT03333200 United States;
MINGO
Sunshine Care Foundation
2017 - NCT03019458 Philippines;
Pantethine
Department of Pediatrics, Peking University First Hospital
2018 - ChiCTR1900021076 China;
RE-024
RETROPHIN, INC
2017 Phase 3 EUCTR2016-001955-29-IT Canada;Czech Republic;Czechia;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Retrophin, Inc.
2018 Phase 3 EUCTR2016-001955-29-FR Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-GB Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Serbia;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-ES Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-CZ Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-PL Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-NO Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-DE Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
RT001
Retrotope, Inc.
2018 Phase 2/Phase 3 NCT03570931 United States;
Oregon Health and Science University
2019 - NCT04182763 United States;
Deferiprone
Chiesi Canada Corp
2016 - NCT02635841 -
ISTITUTO NEUROLOGICO CARLO BESTA
2008 - EUCTR2008-003059-56-IT Italy;
Deferiprone 80 mg/mL oral solution
ApoPharma Inc
2015 Phase 3 EUCTR2014-001427-79-GB Germany;Italy;United Kingdom;United States;
ApoPharma Inc.
2015 Phase 3 EUCTR2014-001427-79-DE Germany;Italy;United Kingdom;United States;
2013 Phase 3 EUCTR2012-000845-11-IT Germany;Italy;Poland;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000845-11-DE Germany;Italy;Poland;United Kingdom;United States;
Deferiprone 80 mg/mL oral solution (Ferriprox)
ApoPharma Inc
2013 Phase 3 EUCTR2012-000845-11-GB Germany;Italy;Poland;United Kingdom;United States;
Deferiprone oral solution
ApoPharma
2014 Phase 3 NCT02174848 Germany;Italy;United Kingdom;United States;
2012 Phase 3 NCT01741532 Germany;Italy;Poland;United Kingdom;United States;
Deferiprone treated
First Affiliated Hospital of Fujian Medical University
2019 Early Phase 1 NCT04184453 China;
Desipramine
Duke University
2019 Phase 4 NCT03726996 United States;
FERRIPROX*100CPR RIV
ISTITUTO NEUROLOGICO CARLO BESTA
2008 - EUCTR2008-003059-56-IT Italy;
FOSMETPANTOTENATE DRUG SUBSTANCE
Retrophin, Inc.
2018 Phase 3 EUCTR2016-001955-29-FR Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-GB Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Serbia;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-CZ Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-PL Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-NO Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-DE Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Ferriprox
ApoPharma Inc
2015 Phase 3 EUCTR2014-001427-79-GB Germany;Italy;United Kingdom;United States;
Fosmetpantotenate
Retrophin, Inc.
2017 Phase 3 EUCTR2016-001955-29-ES Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Fosmetpantotenate (RE-024)
Travere Therapeutics, Inc.
2017 Phase 3 NCT03041116 Canada;Czechia;France;Germany;Italy;Norway;Poland;Spain;United States;
Fosmetpantotenato
RETROPHIN, INC
2017 Phase 3 EUCTR2016-001955-29-IT Canada;Czech Republic;Czechia;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Hematopoetic Stem Cell Transplantation
University of Pittsburgh
2012 - NCT03333200 United States;
MINGO
Sunshine Care Foundation
2017 - NCT03019458 Philippines;
Pantethine
Department of Pediatrics, Peking University First Hospital
2018 - ChiCTR1900021076 China;
RE-024
RETROPHIN, INC
2017 Phase 3 EUCTR2016-001955-29-IT Canada;Czech Republic;Czechia;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
Retrophin, Inc.
2018 Phase 3 EUCTR2016-001955-29-FR Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-GB Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Serbia;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-ES Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001955-29-CZ Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-PL Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-NO Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-001955-29-DE Canada;Czech Republic;France;Germany;Italy;Norway;Poland;Spain;United Kingdom;United States;
RT001
Retrotope, Inc.
2018 Phase 2/Phase 3 NCT03570931 United States;